Essential role of autophagy in restricting poliovirus infection revealed by identification of an ATG7 defect in a poliomyelitis patient

Autophagy. 2021 Sep;17(9):2449-2464. doi: 10.1080/15548627.2020.1831800. Epub 2020 Oct 20.

Abstract

Paralytic poliomyelitis is a rare disease manifestation following poliovirus (PV) infection. The disease determinants remain largely unknown. We used whole exome sequencing to uncover possible contributions of host genetics to the development of disease outcome in humans with poliomyelitis. We identified a patient with a variant in ATG7, an important regulatory gene in the macroautophagy/autophagy pathway. PV infection did not induce a prominent type I interferon response, but rather activated autophagy in neuronal-like cells, and this was essential for viral control. Importantly, virus-induced autophagy was impaired in patient fibroblasts and associated with increased viral burden and enhanced cell death following infection. Lack of ATG7 prevented control of infection in neuronal-like cells, and reconstitution of patient cells with wild-type ATG7 reestablished autophagy-mediated control of infection. Collectively, these data suggest that ATG7 defect contributes to host susceptibility to PV infection and propose autophagy as an unappreciated antiviral effector in viral infection in humans.

Keywords: ATG7; autophagy; host genetics; innate immunity; neuronal-like cells; poliomyelitis; poliovirus; whole exome sequencing.

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Autophagy / genetics
  • Autophagy-Related Protein 7 / genetics
  • Humans
  • Interferon Type I*
  • Neurons
  • Poliomyelitis* / genetics
  • Poliomyelitis* / prevention & control
  • Poliovirus* / genetics

Substances

  • Interferon Type I
  • ATG7 protein, human
  • Autophagy-Related Protein 7

Grants and funding

This work was supported by the Aarhus Universitets Forskningsfond [AUFF-E-215-FLS-8-66]; European Research Council [ERC-AdG ENVISION; 786602]; Lundbeckfonden [R268-2016-3927]; Lundbeckfonden [R198-2015-171]; Novo Nordisk Fonden [NNF18OC0030274]; Sundhed og Sygdom, Det Frie Forskningsråd [4004-00047B].